Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Long-Term Investments (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Long-Term Investments for 7 consecutive years, with $410.3 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments rose 1.1% to $410.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $410.3 million through Dec 2025, up 1.1% year-over-year, with the annual reading at $410.3 million for FY2025, 1.1% up from the prior year.
  • Long-Term Investments hit $410.3 million in Q4 2025 for IDEAYA Biosciences, up from $350.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $410.3 million in Q4 2025 to a low of $7.7 million in Q3 2022.
  • Historically, Long-Term Investments has averaged $162.6 million across 5 years, with a median of $114.4 million in 2021.
  • Biggest five-year swings in Long-Term Investments: skyrocketed 2375.99% in 2021 and later tumbled 93.66% in 2022.
  • Year by year, Long-Term Investments stood at $121.3 million in 2021, then plummeted by 93.14% to $8.3 million in 2022, then skyrocketed by 1192.44% to $107.5 million in 2023, then soared by 277.55% to $405.8 million in 2024, then rose by 1.1% to $410.3 million in 2025.
  • Business Quant data shows Long-Term Investments for IDYA at $410.3 million in Q4 2025, $350.0 million in Q3 2025, and $322.1 million in Q2 2025.